Highly active engineered IgG3 antibodies against SARS-CoV-2.
Kallolimath S, Sun L, Palt R, Stiasny K, Mayrhofer P, Gruber C, Kogelmann B, Chen Q, Steinkellner H.
Kallolimath S, et al. Among authors: sun l.
Proc Natl Acad Sci U S A. 2021 Oct 1;118(42):e2107249118. doi: 10.1073/pnas.2107249118.
Proc Natl Acad Sci U S A. 2021.
PMID: 34599091
Free PMC article.